Comera Life Sciences Holdings Inc.

2.69+0.0500+1.89%Vol 291.74K1Y Perf -
Jul 1st, 2022 16:00 DELAYED
BID2.68 ASK2.74
Open2.63 Previous Close2.64
Pre-Market- After-Market2.68
 - -  -0.01 -0.37%
Target Price
- 
Analyst Rating
— — 0.00
Potential %
- 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
15.30 
Earnings Rating
Market Cap51.34M 
Earnings Date
-
Alpha Standard Deviation
Beta 

Today's Price Range

2.582.84

52W Range

1.1111.44

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Neutral
Performance
1 Week
-18.48%
1 Month
14.47%
3 Months
-
6 Months
-
1 Year
-
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
CMRA2.690.05001.89
AAPL138.932.21001.62
GOOG2 181.62-5.8300-0.27
MSFT259.582.75001.07
XOM87.551.91002.23
WFC39.920.75001.91
JNJ179.522.01001.13
FB196.640.99000.51
GE63.54-0.1300-0.20
JPM114.051.44001.28
Earnings HistoryEstimateReportedSurprise %
----
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume291.74K
Shares Outstanding19.09K
Shares Float19.09M
Trades Count1.85K
Dollar Volume787.90K
Avg. Volume4.60M
Avg. Weekly Volume701.98K
Avg. Monthly Volume7.27M
Avg. Quarterly Volume5.83M

Comera Life Sciences Holdings Inc. (NASDAQ: CMRA) stock closed at 2.69 per share at the end of the most recent trading day (a 1.89% change compared to the prior day closing price) with a volume of 291.74K shares and market capitalization of 51.34M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 0 people. Comera Life Sciences Holdings Inc. CEO is Jeffrey S. Hackman.

The one-year performance of Comera Life Sciences Holdings Inc. stock is %, while year-to-date (YTD) performance is %. CMRA stock has a five-year performance of %. Its 52-week range is between 1.11 and 11.44, which gives CMRA stock a 52-week price range ratio of 15.30%

Comera Life Sciences Holdings Inc. currently has a PE ratio of -7.60, a price-to-book (PB) ratio of -, a price-to-sale (PS) ratio of 136.54, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -167.95%, a ROC of -% and a ROE of 48.74%. The company’s profit margin is -%, its EBITDA margin is -1 703.90%, and its revenue ttm is $415.17 Thousand , which makes it $0.02 revenue per share.

Of the last four earnings reports from Comera Life Sciences Holdings Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Comera Life Sciences Holdings Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Comera Life Sciences Holdings Inc. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Comera Life Sciences Holdings Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Comera Life Sciences Holdings Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Comera Life Sciences Holdings Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 26.42, ATR14 : 0.63, CCI20 : -2.48, Chaikin Money Flow : 0.09, MACD : 0.08, Money Flow Index : 96.15, ROC : 1.51, RSI : 29.00, STOCH (14,3) : 34.42, STOCH RSI : 0.17, UO : 28.57, Williams %R : -65.58), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Comera Life Sciences Holdings Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating-
0.00
-
0.00
-
0.00

Comera Life Sciences Holdings Inc.

Comera Life Sciences Holdings Inc is a pre-clinical biotechnology company dedicated to promoting a formulation science and technology to transform essential biologic medicines from intravenous to subcutaneous forms. Comera's internal portfolio of proprietary techniques known as the SQore platform is designed to potentially transform essential biologic medicines from intravenous (IV) to subcutaneous (SQ) forms, and optimize current versions of subcutaneous biologics, and produce biosimilar versions of existing subcutaneous products. It also collaborates with pharmaceutical and biotechnology companies, applying the SQore platform to the Company's partners' biologic medicines to deliver enhanced formulations that facilitate self-injectable care.

CEO: Jeffrey S. Hackman

Telephone: +1 617 871-2101

Address: 12 Gill Street, Woburn 01801, MA, US

Number of employees: 0

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

100%0%

Bearish Bullish

50%50%

News

Stocktwits